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It is known that speciﬁc alteration of rhythm in temperature (SART) stress produces somatic pain.
However, it remains to be investigated whether SART stress induces visceral pain. In this study, we
investigated the visceral hypersensitivity in the SART stress model by pharmacological tools and het-
erotopical nociception. Four-week-old SpragueeDawley rats were exposed to repeated cold stress.
Visceral pain was measured by visceromotor response to colorectal distension, and the effects of alo-
setron and duloxetine on visceral pain were investigated in SART rats. Heterotopical nociception was
given by capsaicin injection into the left forepaw to induce diffuse noxious inhibitory controls (DNIC).
SART stress induced visceral hypersensitivity that was sustained at minimum for one week. In phar-
macological analysis, alosetron and duloxetine improved SART stress-induced visceral hypersensitivity.
Heterotopical nociception induced DNIC in normal conditions, but was disrupted in SART rats. On the
other hand, RMCP-II mRNA in distal colon was not affected by SART stress. In conclusion, SART rats
exhibit several features of visceral pain in IBS, and may be a useful model for investigating the central
modiﬁcation of pain control in IBS.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Irritable bowel syndrome (IBS), as deﬁned by Rome III diagnostic
criteria, affects 10%e20% of the general population and accounts for
25%e50% of all patients visiting gastrointestinal clinics (1,2). It is
characterized by chronic abdominal pain and altered bowel habits
in the absence of any known organic pathology and is often co-
morbid with depression and anxiety. Stress aggravates IBS symp-
toms; therefore, managing stress is an important part of IBS
therapy. Fibromyalgia (FM), a disorder characterized bywidespread
musculoskeletal pain accompanied by fatigue and poor sleep, is
also triggered by stress and frequently coexists with IBS.
One common pathophysiological characteristic of both diseases
is dysfunction of diffuse noxious inhibitory controls (DNIC)
(3e7,14,15). DNIC are supraspinal mechanism controlling brainstem
opioidergic and monoaminergic neurons related to descending
pain inhibitory systems, which suppress pain in one region byy Unit, Takeda Pharmaceutical
Kanagawa, 251-8555, Japan.
. Tsukimi).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).heterotopic noxious stimuli (8,9,20). Hypoactivity of these
descending pain inhibitory systems may underlie the chronic pain
associated with many diseases, including IBS and FM. Therefore,
measuring the function of endogenous pain inhibitory systems by
evaluating the strength of DNIC may be useful for understanding
pathophysiology of pain in IBS and FM.
The speciﬁc alteration of rhythm in temperature (SART) rat
model, established by subjecting a rat to repeated cold stress, is
considered a potential animal model of FM (10,11). Although IBS
patients have a deﬁcit in DNIC similar to FM patients (14,15), to date
there are no reports examining DNIC in animalmodels of IBS. In this
study, to characterize SART rats as an IBS model, we investigated
hypersensitivity of visceral pain and drug responses. Then we
examined central modulation of visceral pain by DNIC and pe-
ripheral alteration by measuring RMCP-II expression level in distal
colon.
2. Materials and methods
2.1. Experimental animals
Three- or ﬁve-week-old male SpragueeDawley (SD) rats were
obtained from Clea Japan Inc. (Meguro-ku, Tokyo) and housed inr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
Y. Itomi et al. / Journal of Pharmacological Sciences 129 (2015) 26e30 27stainless cages under a 12-h darkelight cycle in a temperature- and
humidity-controlled environment (24 ± 1 C, 55 ± 5% humidity).
After one week of acclimatization, rats were used for tests. All an-
imal experiments were conducted according to internal Animal
Experimentation Ethics Committee guidelines.
2.2. Reagents
Alosetron hydrochloride (Bosche Scientiﬁc, New Brunswick,
New Jersey, USA) and duloxetine (Luna Chemicals, Hangzhou,
China) were dissolved in 0.5% methylcellulose 400 (WAKO Chem-
icals, Osaka-city, Osaka) and administered orally. To prepare
capsaicin solution stock (50 mg/mL), capsaicin (Wako Chemicals)
was ﬁrst dissolved in ethanol (Wako Chemicals), and Tween80
(WAKO Chemicals) was added to the solution; the volume of
Tween80 added was the same as that of ethanol. The stock was
stored at 4 C and diluted with saline (Otsuka Pharmaceutical,
Chiyoda-ku, Tokyo) to 2.5 mg/mL immediately before injection.
Capsaicin solution was injected into the intraplantar region of the
forepaw (150 mg in 60 mL) under isoﬂurane anesthesia.
2.3. Loading SART stress
Four-week-old male SD rats were exposed to alternating one-
hour periods of cold (0 C) and room temperature (24 C) from
9:30 h16:30 h by repeated transfer into and out of a thermo-
controlled incubator (MIR-554, SANYO, Moriguchi-city, Osaka),
followed by sustained cold from 16:30 h9:30 h. This cycle was
repeated for four days to establish the SART stress model (Fig. 1).
Rats were given ad libitum access to food and water during the
stress session. After the stress session, rats were maintained at
24 C and used for pain tests.
2.4. Visceromotor response (VMR) measurements
A latex balloon (3 cm) lubricated with lubricant jelly (Johnson
and Johnson, New Brunswick, New Jersey) was inserted into the
distal colon through the anus, and the distal end of the balloonwas
positioned at 2 cm from the anus. The balloon was secured in the
distal colon by taping the balloon catheter to the base of the tail,
and the catheter was covered with a metallic spring to protect it
from rat bites. Control or SART rats were placed in a plastic cage for
30 min before starting the colorectal distension (CRD) procedure.
The CRD procedure consisted of ascending phasic isobaric disten-
sions of the balloon (5 mmHg increase per step in 30 s; Fig. 2,
leftmost panel). Visceral pain in response to CRD was quantiﬁed by
the visceromotor response (VMR). Visceral pain threshold was
deﬁned as the lowest balloon pressure of three sequential disten-
tion pressures that elicited a reliable VMR. The effects of alosetron
and duloxetine on visceral pain were assayed ﬁve and 11 days after
termination of the SART stress protocol, respectively. ForFig. 1. Modulation of exposure temperature for induction of SART stress. Four-week-old
maintained at 0 C from 16:30e9:30 for four consecutive days. After the completion of SARassessments of both drugs, SART rats were divided into three
groups on the basis of the VMR threshold prior to drug adminis-
tration. Alosetron was administered orally one hour prior to CRD
and duloxetine three hours prior to CRD based on drug response
properties established in previous reports (12,13).
2.5. Assessment of DNIC
To measure the strength of DNIC, rats were subjected to a CRD
three times at a pressure of 5 mmHg higher than that of the VMR
threshold. If rats exhibited VMR twice or more at a particular
pressure, the pressure was taken as the baseline or pre DNIC value.
If not, the CRD pressure was raised another 5 mmHg until the cri-
terion response was achieved. Under isoﬂurane anesthesia, 150 mg/
rat of capsaicin was injected into the intraplantar region of the left
forepaw as a conditioning stimulus (16). Sixty minutes later, rats
were subjected to CRD at pre DNIC value. If rats showed a VMR
twice or more that pressure was considered as the post DNIC value.
If not, the CRD was raised by 5 mmHg until rats showed a VMR at
least twice or more.
2.6. Expression analysis of RMCP-II mRNA
To investigate peripheral alteration in colon of SART rats, a
marker of mast cell, RMCP-II level was measured. Mucosa and
muscle from the distal colon were removed 13 days after the
completion of SART stress protocol. Total mRNA was extracted ac-
cording to the protocol of ISOGEN (Nippon Gene, Chiyoda-ku,
Tokyo), and the expression level of RMCP-II mRNA was deter-
mined using reverse transcription-polymerase chain reaction (RT-
PCR) and normalized to that of GAPDH.
2.7. Data analysis
Data are expressed asmean± SE. All results were analyzed using
the statistical analysis software preclinical package version 5 (SAS
institute Inc., Cary, NC, USA). Student's t-test, paired t-test or Wil-
liam's test was conducted as appropriate and P  0.05 for t-tests or
P  0.025 for Williams's tests was considered statistically
signiﬁcant.
3. Results
3.1. Visceral hypersensitivity in SART rats
Rats subjected to SART stress exhibited decreased body weight
gain during the period of SART stress protocol (cold stress for 4
days) compared with age-matched control rats. However, after the
completion of SART stress protocol, the rate of body weight gain in
SART rats was almost the same as that in control rats (data not
shown). Immediately after ﬁnishing the SART stress protocol, ratsrats were exposed to alternating 1-h periods of 0 C and 24 C from 9:30e16:30 and
T stress, rats were maintained at 24 C during pain threshold test.
Threshold + 5 mmHg Add 5 mmHg
30 sec
5 mmHg
Detection of 
VMR threshold
Threshold + 5 mmHg
pre post
capsaicin/veh injection
into forepaw
if not
responded
Fig. 2. Methods for establishing threshold of VMR and DNIC in rats. VMR threshold to colorectal distention (CRD) was determined by stepwise increases in colorectal balloon
pressure (5 mmHg increments every 30 s). To measure baseline or pre DNIC values, rats were subjected to three CRDs at a pressure of 5 mmHg higher than VMR threshold or at a
higher pressure until VMR was elicited reliably. One hour after injection of vehicle or capsaicin, rats were subjected to the same CRD pressure as the pre value. If that pressure
elicited a VMR twice or more in three sessions, it was deﬁned as the post value. If not, the CRD pressure was raised another 5 mmHg until the rat responded reliably.
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pressure of CRD induced a reliable VMR in SART rats comparedwith
control rats, and this visceral hypersensitivity sustained for at least
oneweek (Fig. 3). In a separate series of experiments, we found that
the visceral hypersensitivity of SART rats was sustained for at least
17 days after the completion of SART stress protocol (Fig. 5).3.2. Pharmacological analysis of visceral hypersensitivity in SART
rats
Analgesic effects of the IBS drug alosetron and antidepressant
duloxetine on visceral hypersensitivity were investigated in SART
ratsﬁvedays and11daysafter thecompletionofSARTstressprotocol,
respectively (Fig. 4). Alosetron (po) increased VMR threshold in SART
rats in a dose-dependentmanner by 30.4% at 3mg/kg (p¼ 0.147) and
by 60.9% at 10 mg/kg (p ¼ 0.026). Similarly, duloxetine (po) also
improved visceral hypersensitivity in a dose-dependent manner
with improvement rates of 28.0% at 10mg/kg (p¼ 0.115) and64.0% at
30 mg/kg with statistical signiﬁcance (p ¼ 0.007).3.3. Capsaicin-induced DNIC in control and SART rats
We ﬁrst investigated capsaicin-induced DNIC on visceral pain in
control rats to establish the optimal condition for inducing DNIC.0
10
20
30
40
50
60
-4 -2 0 2 4 6 8
VM
R
 th
re
sh
ol
d 
(m
m
H
g)
After SART stress (day)
control
SART
***
*** ***
Fig. 3. Time course of change in mean VMR threshold in control and SART rats. The
animals were either kept in normal housing at 24 C or exposed to SART stress and the
thresholds of VMR to CRD were determined on the designated days. Data are presented
as mean ± SE (n ¼ 7e14). ***P < 0.001 vs. pre value (paired t-test). Visceral hyper-
sensitivity as indicated by the lower VMR threshold maintained at least one week in
SART rats.While vehicle injection into the left forepaw had no effect on VMR
threshold in response to CRD, injection of capsaicin (150 mg/rat)
raised the threshold signiﬁcantly (Fig. 5), indicating DNIC-related
analgesia in visceral pain. We then examined DNIC in SART rats
17 days after the completion of SART stress protocol. In contrast to
control rats, SART rats demonstrated no change in VMR threshold
in response to CRD after capsaicin injection (Fig. 5), indicating a
profound dysfunction of DNIC in SART rats.
3.4. Expression of RMCP-II mRNA in the distal colon of SART rats
Distal colons were collected from SART rats 13 days after the
completion of the stress protocol, and expression levels of RMCP-II
mRNA in mucosa and muscle were measured by RT-PCR. It is
considered that low grade inﬂammation and mast cell are associ-
ated with visceral pain symptoms in certain IBS patient population
(22e25,29,30). Therefore, we measured the expression level of
RMCP-II mRNA as a general marker for mast cell in the distal colon
(27). However, no difference in the expression levels was observed
in mucosa and muscle between control and SART rats (Fig. 6),
suggesting that SART stress did not increase the number of mast
cells in the distal colon.
4. Discussion
Long-lasting visceral hypersensitivity to CRD, as revealed by
decreased VMR threshold, was observed in SD rats exposed to SART
stress. The drugs being effective in IBS pain such as alosetron and
duloxetine improved visceral hypersensitivity in SART rats. In
addition, capsaicin-induced DNIC on visceral pain were deﬁcient in
SART rats. Contrarily, the expression level of RMCP-II mRNA in the
colon of SART rats was normal. These ﬁndings indicate that SART
rats possess several features of visceral pain in IBS, and may be a
useful model for investigating the central modiﬁcation of pain
control in IBS.
Similar to FM, IBS symptoms are aggravated by stress, and both
diseases coexist in the same patients. Moreover, it is reported that
both diseases demonstrate deﬁcient DNIC, and this may reveal a
common pathogenic mechanism of refractory pain (4,14,15,21). In
this study, we investigated whether SART rats possess any aspects
of IBS pain from the viewpoints of drug responses, central pain
modiﬁcation, and peripheral involvement.
First of all, we investigated whether visceral hypersensitivity
occurs in SART rats. When SART stress was given to rats, a signiﬁ-
cant decrease in VMR threshold was observed, indicating that
visceral hypersensitivity was established. Interestingly, this visceral
hypersensitivity was sustained at least a week even after the
cessation of SART stress whereas decreased body weight gain
during SART stresswas recovered immediately after the completion
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Fig. 4. Effects of alosetron and duloxetine on SART stress-induced visceral hypersensitivity. VMR thresholds were measured one hour after oral alosetron (A) or three hours
after oral duloxetine (B) in SART rats ﬁve or 11 days after SART stress protocol, respectively. Both drugs caused a dose-dependent decrease in visceral hypersensitivity to CRD as
indicated by higher VMR thresholds compared to vehicle (veh)-treated SART rats. Data are presented as mean ± SE (n ¼ 6). *P < 0.05 vs. control (Student's t-test), #P < 0.05 vs.
vehicle-treated SART rats (Williams test).
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Fig. 5. Capsaicin-induced DNIC on visceral pain in control and SART rats. Pre values
of VMR threshold were determined before the injection of vehicle or 150 mg capsaicin
in control and SART rats 17 days after SART stress protocol. One hour after the injection,
post VMR threshold values were determined. Controls rats exhibited an increased
threshold of VMR following capsaicin (cap) injection but not after vehicle (veh) in-
jection, indicative of DNIC induction. In contrast, threshold of VMR was unchanged in
SART rats, indicating failure of DNIC induction. Data are presented as mean ± SE
(n ¼ 6). *P < 0.05 vs. pre value (paired-t test), #P < 0.05 vs. control (Student's t-test).
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Fig. 6. Expression levels of RMCP-II mRNA in distal colon of control and SART rats. Muc
day after SART stress protocol. Expression level of RMCP-II mRNA was analyzed by RT-PCR.
rats. Data are presented as mean ± SE (n ¼ 5).
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visceral hypersensitivity in rats.
In order to characterize SART stress-induced visceral hyper-
sensitivity, we investigated the effects of alosetron and duloxetine
on visceral hypersensitivity. Alosetron, a drug approved for the
treatment of diarrhea-predominant IBS, is reported to alleviate
visceral pain in clinic (28). Duloxetine also demonstrated certain
efﬁcacy in abdominal pain in IBS patients in clinical studies
(17e19). As the results, both alosetron and duloxetine improved
visceral hypersensitivity in SART rats. Therefore, it is likely that
SART stress-induced visceral hypersensitivity resemble clinical
setting of IBS in regard to drug responses.
In another series of experiments, we examined DNIC in SART
rats to investigate endogenous pain inhibitory mechanismwhich is
attenuated in IBS patients (14,15). In this case, we used capsaicin
injection in the forepaw as a heterotopic nociception to induce
DNIC. Heterotopical treatment of capsaicin had been reported to
induce endogenous analgesia (16). We also conﬁrmed that
capsaicin-induced DNIC in somatic pain were blocked by several
pharmacological treatments, such as naloxone (ip and icv), 5-HT1A
receptor antagonist WAY-100635 (intrathecally), and yohimbine
(intrathecally) as unpublished observations. Based on above, it can
be speculated that the ectopic capsaicin-induced DNIC are medi-
ated by descending pain inhibitory systems from brain to spinal
cord. In this study, we found that capsaicin pretreatment increased
pain threshold in response to CRD in normal rats, suggesting that0
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There were no signiﬁcant differences of RMCP-II expression between control and SART
Y. Itomi et al. / Journal of Pharmacological Sciences 129 (2015) 26e3030DNIC are present and detectable even on visceral pain in rats.
Therefore, it is reasonable to speculate that descending pain
inhibitory systems regulate visceral nociceptive input as well as
somatic one. Surprisingly, SART rats failed to exhibit measurable
DNIC on visceral pain induced by CRD. This phenomenon is
consistent with the clinical ﬁndings that IBS patients have
abnormal central modulation on visceral pain (4,5).
In addition to changes in central pain modulation in SART rats,
we also examined peripheral changes in response to SART stress.
Because recent studies on gut biopsy tissues from IBS patients have
found evidence of low grade mucosal inﬂammation (22e25,29,30).
In fact, some of these reports demonstrated that visceral pain in IBS
patients was correlated with mast cell count in colon (22,25).
Therefore, we measured the expression level of RMCP-II mRNA as a
marker for mast cell in the distal colon. Contrary to our expectation,
no difference in the expression levels was detected between control
and SART rats, indicating that SART stress had little effect on pe-
ripheral organ.
In the present study, we found SART rats showed chronic
visceral hypersensitivity and deﬁcient DNIC, but not mast cell
upregulation in the colon. These ﬁndings indicate the visceral hy-
persensitivity in SART rats may be caused by an alteration in CNS
pain processing systems rather than peripheral involvement. In the
previous report, however, water avoidance stress (WAS)-induced
IBS model showed both sustained visceral hypersensitivity and
increase inmast cell number (26). Hence it's worthwhile examining
DNIC in WAS model to elucidate whether WAS impairs central pain
modiﬁcation resulting in chronic visceral hypersensitivity.
In conclusion, SART rats exhibit several features of IBS, including
chronic visceral hypersensitivity, drug responses, and hypoactivity
of central pain regulation systems. These ﬁndings may underscore
the validity of this model for investigating pathophysiology of
central pain modiﬁcation in IBS.
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